Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
Human Immunology Section, Vaccine Research Center, National Institutes of Health, Bethesda, MD, United States of America.
PLoS One. 2021 Jul 26;16(7):e0255096. doi: 10.1371/journal.pone.0255096. eCollection 2021.
The COVID-19 pandemic raises the need for diverse diagnostic approaches to rapidly detect different stages of viral infection. The flexible and quantitative nature of single-molecule imaging technology renders it optimal for development of new diagnostic tools. Here we present a proof-of-concept for a single-molecule based, enzyme-free assay for detection of SARS-CoV-2. The unified platform we developed allows direct detection of the viral genetic material from patients' samples, as well as their immune response consisting of IgG and IgM antibodies. Thus, it establishes a platform for diagnostics of COVID-19, which could also be adjusted to diagnose additional pathogens.
COVID-19 大流行提出了对多种诊断方法的需求，以快速检测病毒感染的不同阶段。单分子成像技术的灵活性和定量性质使其成为开发新诊断工具的理想选择。在这里，我们提出了一种基于单分子的、无酶检测 SARS-CoV-2 的概念验证。我们开发的统一平台允许直接从患者样本中检测病毒的遗传物质，以及由 IgG 和 IgM 抗体组成的免疫反应。因此，它为 COVID-19 的诊断建立了一个平台，也可以调整该平台来诊断其他病原体。
